

IMP731

Name: IMP731

Synonyms: GSK2831781

Indication: Autoimmune

Company: Immuntep; GlaxoSmithKline

IMP731, a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity. IMP731 has demonstrated potency at low doses in preclinical models of T-cell mediated inflammation and could represent a new therapeutic approach to the treatment of autoimmune disease. IMP731 has been licensed by Immuntep to GlaxoSmithKline, or GSK, under a license and research agreement

Under this license, GSK has the exclusive development right of IMP731 and has agreed to fund all the development costs. In exchange for the grant of this license, Immuntep received from GSK an undisclosed upfront payment and has the right to receive potential milestone payments up to an aggregate amount of £64 million, minus the upfront payment amount. In addition, Immuntep also has the right to receive potential single-digit tiered royalty payments. In January 2015, we collected our first milestone payment from GSK for the development of GSK2831781, an anti-LAG-3 antibody derived from IMP731. The product candidate is currently in a Phase I clinical trial.